Scholarlink

Background <p>Epidermal growth factor receptor (<i>EGFR</i>) exon 19 insertions (19ins) represent a unique subclass of exon 19 alterations that has a relatively low frequency. Here, we aimed to elucidate the molecular characteristics and response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in lung cancer patients with <i>EGFR</i> 19ins.</p> Methods <p>Next-generation sequencing was performed to profile the molecular characteristics of 83 non-small cell lung cancer (NSCLC) patients with <i>EGFR</i> 19ins. Detailed molecular profiling and efficacy analyses were performed on these patients, with comparisons to 68 <i>EGFR</i> 19 deletion (19del) patients. Potential resistance mechanisms were also explored.</p> Results <p>The prevalence of <i>EGFR</i> 19ins mutations was 0.17% of all the primary NSCLC patients. <i>EGFR</i> 19ins variants identified were I740_K745dup (86.7%) and K745_E746insVPVAIK (13.3%). Concurrent mutations frequently observed were in <i>TP53</i> (50.6%), <i>CDKN2A</i> (12.0%), <i>PIK3CA</i> (10.8%), <i>LRP1B</i> (8.4%), and <i>SMAD4</i> (8.4%). Notably, <i>CTNNB1</i> was significantly associated with 19ins (<i>p</i> = 0.043). Efficacy analysis showed median progression-free survival (mPFS) for <i>EGFR</i> 19ins patients receiving first-line EGFR-TKI treatment was significantly shorter than for <i>EGFR</i> 19del patients (hazard ratio (HR) 1.98, <i>p</i> = 0.005). Gefitinib was significantly less effective compared to other first-generation TKIs (HR 19.86, <i>p</i> &lt; 0.001). Furthermore, osimertinib did not generate favorable outcomes as 19dels in the first-line setting either (<i>p</i> = 0.025). Post-treatment samples revealed higher occurrences of <i>TP53</i> mutations (84.6%) and presence of <i>EGFR</i> T790M (23.1%) at progression, with case studies highlighting osimertinib’s limited efficacy post-first-line treatment.</p> Conclusions <p>Comprehensive analysis of <i>EGFR</i> 19ins in lung cancer patients revealed genomic characteristics and clinical response, helping better inform clinical action and might facilitate the development of more precise therapeutic options for patients with these uncommon driver mutations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月29日

查看全文
  • Yang Li,
  • Yunfeng Ni,
  • Feng Lv,
  • Yan Shi,
  • Yedan Chen,
  • Xiaoying Wu,
  • Jiaohui Pang,
  • Long Huang,
  • Yang Shao,
  • Tao Wang,
  • Jie Min,
  • Yang Song

摘要

Background

Epidermal growth factor receptor (EGFR) exon 19 insertions (19ins) represent a unique subclass of exon 19 alterations that has a relatively low frequency. Here, we aimed to elucidate the molecular characteristics and response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in lung cancer patients with EGFR 19ins.

Methods

Next-generation sequencing was performed to profile the molecular characteristics of 83 non-small cell lung cancer (NSCLC) patients with EGFR 19ins. Detailed molecular profiling and efficacy analyses were performed on these patients, with comparisons to 68 EGFR 19 deletion (19del) patients. Potential resistance mechanisms were also explored.

Results

The prevalence of EGFR 19ins mutations was 0.17% of all the primary NSCLC patients. EGFR 19ins variants identified were I740_K745dup (86.7%) and K745_E746insVPVAIK (13.3%). Concurrent mutations frequently observed were in TP53 (50.6%), CDKN2A (12.0%), PIK3CA (10.8%), LRP1B (8.4%), and SMAD4 (8.4%). Notably, CTNNB1 was significantly associated with 19ins (p = 0.043). Efficacy analysis showed median progression-free survival (mPFS) for EGFR 19ins patients receiving first-line EGFR-TKI treatment was significantly shorter than for EGFR 19del patients (hazard ratio (HR) 1.98, p = 0.005). Gefitinib was significantly less effective compared to other first-generation TKIs (HR 19.86, p < 0.001). Furthermore, osimertinib did not generate favorable outcomes as 19dels in the first-line setting either (p = 0.025). Post-treatment samples revealed higher occurrences of TP53 mutations (84.6%) and presence of EGFR T790M (23.1%) at progression, with case studies highlighting osimertinib’s limited efficacy post-first-line treatment.

Conclusions

Comprehensive analysis of EGFR 19ins in lung cancer patients revealed genomic characteristics and clinical response, helping better inform clinical action and might facilitate the development of more precise therapeutic options for patients with these uncommon driver mutations.